BellBrook Labs Webinar: Development of Ectonucleotidase Assay Methods Using the Transcreener® HTS Assay Platform

Share Article

Ectonucleotidases are emerging as promising immuno-oncology targets and require robust homogeneous assays for further study. BellBrook Senior Application Scientist, Meera Kumar, will describe how Transcreener® HTS assays can be used to identify and characterize ectonucleotidase inhibitors.

BellBrook Labs Logo

BellBrook Labs is Dedicated to Drug Discovery by Providing Innovative HTS Assays

Join us for a webinar on Tuesday, May 23 at 11:00 AM CDT: Development of Ectonucleotidase Assay Methods Using the Transcreener® HTS Assay Platform

Register for the Free Webinar

Ectonucleotidases are plasma membrane-bound enzymes with externally oriented active sites that metabolize nucleotides to nucleosides. One example is ectonucleoside triphosphate diphosphohydrolase-1, also known as CD39, ENTPD1, or NTPDase1. CD39 hydrolyzes ATP and ADP to AMP. Other ectonucleotidases such as CD73 process the AMP further into adenosine, which is an important signaling molecule for immunosuppression in the tumor microenvironment. For this reason, ectonucleotidases are emerging as promising immuno-oncology targets, with a number of groups working on small molecule and antibody-based inhibitors. As the only HTS method capable of direct detection of nucleotides, the Transcreener® platform is uniquely suited for measuring ectonucleotidase activity with the high sensitivity and low levels of interference required for a successful HTS campaign.

In this webinar we will discuss:

  • Assay development for CD39 using the Transcreener® AMP/GMP Assay with fluorescence polarization and TR-FRET readouts
  • Demonstrated assay robustness for use in high-throughput screening
  • Inhibitor potency profiling for CD39
  • Recent external publications using Transcreener® HTS assays for studying ectonucleotidase activity

Register for the Free Webinar

After registering, you will receive a confirmation e-mail containing more information about joining the webinar on May 23rd.

About BellBrook Labs:

BellBrook Labs is dedicated to accelerating drug discovery and biological research by providing innovative high throughput screening solutions. Transcreener® is a universal, homogeneous biochemical assay platform based on detection of nucleotides that makes it easy to screen thousands of different enzymes. These include validated targets like kinases, as well as emerging targets like ATPases, GTPases, methyltransferases, and glycosyltransferases. Detection reagents and drug discovery services from BellBrook Labs help researchers progress toward more effective therapies for cancer and other debilitating diseases.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Justin Brink
BellBrook Labs
+1 (608) 227-4519
Email >
Visit website